Wize Pharma Gets Green Light to Start Phase 4 Trial of Eye Drops in Sjogren’s Patients
The protocol of a Phase 4 trial testing Wize Pharma‘s LO2A eye drops for the treatment of dry eye symptoms in Sjogren’s syndrome patients has received regulatory approval. Clearance from the Institutional Review Board (IRB) means the study is now allowed to start. The double-blind trial (NCT03319420), to be…